- Home
- GECC vs CRDL Comparison
GECC vs CRDL Comparison
Compare GECC & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GECC | CRDL |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.8M | 97.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GECC | CRDL |
|---|---|---|
| Price | $7.03 | $0.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $10.75 | $9.00 |
| AVG Volume (30 Days) | 122.6K | ★ 445.0K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | ★ 21.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $46,553,000.00 | N/A |
| Revenue This Year | $32.16 | N/A |
| Revenue Next Year | $3.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.68 | N/A |
| 52 Week Low | $6.61 | $0.77 |
| 52 Week High | $11.46 | $1.59 |
Technical Indicators
Market Signals| Indicator | GECC | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 40.53 |
| Support Level | $6.61 | $0.88 |
| Resistance Level | $6.94 | $1.03 |
| Average True Range (ATR) | 0.27 | 0.04 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 31.31 | 6.24 |
Price Performance
Historical ComparisonAbout GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.